BR112012030641B8 - Usos e composições para terapia farmacêutica oral - Google Patents
Usos e composições para terapia farmacêutica oralInfo
- Publication number
- BR112012030641B8 BR112012030641B8 BR112012030641A BR112012030641A BR112012030641B8 BR 112012030641 B8 BR112012030641 B8 BR 112012030641B8 BR 112012030641 A BR112012030641 A BR 112012030641A BR 112012030641 A BR112012030641 A BR 112012030641A BR 112012030641 B8 BR112012030641 B8 BR 112012030641B8
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- agents
- oral pharmaceutical
- pharmaceutical therapy
- jejunum
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000001198 duodenum Anatomy 0.000 abstract 2
- 210000001630 jejunum Anatomy 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004267 taurolidine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35018310P | 2010-06-01 | 2010-06-01 | |
| US61/350,183 | 2010-06-01 | ||
| US37031510P | 2010-08-03 | 2010-08-03 | |
| US61/370,315 | 2010-08-03 | ||
| PCT/IB2011/001539 WO2011151722A2 (en) | 2010-06-01 | 2011-06-01 | Methods and compositions for oral pharmaceutical therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012030641A2 BR112012030641A2 (pt) | 2016-08-16 |
| BR112012030641B1 BR112012030641B1 (pt) | 2022-05-24 |
| BR112012030641B8 true BR112012030641B8 (pt) | 2022-06-14 |
Family
ID=45067142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012030641A BR112012030641B8 (pt) | 2010-06-01 | 2011-06-01 | Usos e composições para terapia farmacêutica oral |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9028866B2 (https=) |
| EP (1) | EP2575783B1 (https=) |
| JP (2) | JP5926243B2 (https=) |
| CN (1) | CN103118669B (https=) |
| AU (1) | AU2011262308B2 (https=) |
| BR (1) | BR112012030641B8 (https=) |
| CA (1) | CA2801309C (https=) |
| ES (1) | ES2614878T3 (https=) |
| WO (1) | WO2011151722A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2632248C2 (ru) * | 2012-05-15 | 2017-10-03 | Филипс Лайтинг Холдинг Б.В. | Управление устройствами освещения |
| US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| EP3402527B1 (en) * | 2016-01-11 | 2022-09-28 | CorMedix Inc. | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |
| US11541061B2 (en) | 2016-01-11 | 2023-01-03 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
| US20190381058A1 (en) * | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Methods and compositions for treating neuroblastoma in a juvenile mammalian body |
| SI3709979T1 (sl) | 2017-11-17 | 2025-03-31 | Evonik Operations Gmbh | Postopek za pripravo obložene kapsule s trdo ovojnico |
| JP2021535163A (ja) * | 2018-08-28 | 2021-12-16 | コーメディクス・インコーポレーテッド | タウロリジン加水分解産物による神経芽細胞腫治療 |
| CN113226325A (zh) * | 2018-08-31 | 2021-08-06 | 科医公司 | 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗 |
| WO2020234833A1 (en) | 2019-05-22 | 2020-11-26 | Geistlich Pharma Ag | Method for treating, preventing, inhibiting or reducing cytokine release |
| WO2020234829A1 (en) * | 2019-05-22 | 2020-11-26 | Geistlich Pharma Ag | Methods and compositions for inhibiting gapdh |
| CN111671758A (zh) * | 2020-07-06 | 2020-09-18 | 长春迈灵生物工程有限公司 | 牛磺罗定在制备抗hiv病毒药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
| IE66933B1 (en) * | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| US5972933A (en) * | 1998-01-08 | 1999-10-26 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of treating microbial infections |
| US6555534B1 (en) * | 1998-09-11 | 2003-04-29 | Medpointe Healthcare Inc. | Method and compositions for the control or eradication of Helicobacter pylori |
| US6251896B1 (en) * | 1999-03-24 | 2001-06-26 | Carter-Wallace, Inc. | Compositions and methods for the management of Crohn's disease |
| CA2381425A1 (en) * | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| JP5027369B2 (ja) | 1999-12-06 | 2012-09-19 | ガイストリッヒ ファーマ アーゲー | 腫瘍を治療する方法 |
| US20020004502A1 (en) * | 2000-01-05 | 2002-01-10 | Redmond H. Paul | Treatment of inflammatory bowel disease |
| US20040170617A1 (en) * | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| AU779362B2 (en) * | 2000-10-27 | 2005-01-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| SK287902B6 (sk) * | 2001-01-31 | 2012-03-02 | Evonik Rohm Gmbh | Multiparticulate drug form and method for the preparation thereof |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| US9138408B2 (en) * | 2002-06-21 | 2015-09-22 | L'oreal | Use of taurine for treating alopecia |
| US20060198886A1 (en) * | 2005-03-01 | 2006-09-07 | Jenkins Richard B | Medicament having coated methenamine combined with acidifier |
| WO2007069272A2 (en) * | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| ES2318628T3 (es) * | 2006-07-25 | 2009-05-01 | Claus Herdeis | Preparacion de formulaciones antimicrobianas que comprenden 7-oxa-2-tia-1,5 diazabiciclo(3.3.1)-nonan-2,2-diona. |
-
2011
- 2011-06-01 CN CN201180036488.8A patent/CN103118669B/zh active Active
- 2011-06-01 BR BR112012030641A patent/BR112012030641B8/pt not_active IP Right Cessation
- 2011-06-01 AU AU2011262308A patent/AU2011262308B2/en active Active
- 2011-06-01 CA CA2801309A patent/CA2801309C/en active Active
- 2011-06-01 ES ES11758551.3T patent/ES2614878T3/es active Active
- 2011-06-01 WO PCT/IB2011/001539 patent/WO2011151722A2/en not_active Ceased
- 2011-06-01 US US13/701,372 patent/US9028866B2/en active Active
- 2011-06-01 JP JP2013513002A patent/JP5926243B2/ja active Active
- 2011-06-01 EP EP11758551.3A patent/EP2575783B1/en active Active
-
2016
- 2016-02-29 JP JP2016037487A patent/JP2016155826A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2614878T3 (es) | 2017-06-02 |
| BR112012030641A2 (pt) | 2016-08-16 |
| US9028866B2 (en) | 2015-05-12 |
| CN103118669A (zh) | 2013-05-22 |
| JP2016155826A (ja) | 2016-09-01 |
| WO2011151722A3 (en) | 2012-05-24 |
| US20130089606A1 (en) | 2013-04-11 |
| AU2011262308A1 (en) | 2013-01-10 |
| CA2801309A1 (en) | 2011-12-08 |
| CN103118669B (zh) | 2016-01-13 |
| CA2801309C (en) | 2018-07-17 |
| WO2011151722A2 (en) | 2011-12-08 |
| BR112012030641B1 (pt) | 2022-05-24 |
| EP2575783A2 (en) | 2013-04-10 |
| AU2011262308B2 (en) | 2014-07-31 |
| JP5926243B2 (ja) | 2016-05-25 |
| JP2013527224A (ja) | 2013-06-27 |
| EP2575783B1 (en) | 2017-01-11 |
| HK1183228A1 (zh) | 2013-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012030641B8 (pt) | Usos e composições para terapia farmacêutica oral | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| CY1119140T1 (el) | Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| EA201590835A1 (ru) | Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием | |
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| BRPI0903464B8 (pt) | formulação aquosa de um agente terapêutico e método para criar um dispositivo de aplicação de fármacos | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| BR112015010477A2 (pt) | combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
| NZ711225A (en) | A pharmaceutical formulation comprising omecamtiv mecarbil, processess and uses | |
| CR11724A (es) | Agente para tratar enfermedades | |
| BR112015009504A2 (pt) | inibidores de rock | |
| AR062167A1 (es) | Sistema de administracion gastrorretentivo | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| BR112015003836A2 (pt) | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga | |
| BRPI1010861A8 (pt) | métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica | |
| BR112017016087A2 (pt) | formulações para coxim articular adiposo e métodos de uso das mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/06/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2681 DE 24/05/2022 QUANTO A PRIORIDADE UNIONISTA. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2777 DE 26-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |